Short description
Clinical Data develops and commercializes therapeutics for central nervous system and cardiovascular disorders.
Description
Clinical Data, Inc. is focused on the development and commercialization of therapeutics, with two compounds in the areas of central nervous system and cardiovascular disorders. The Company's late-stage drug candidate is vilazodone, a dual-acting selective and potent serotonin reuptake inhibitor and serotonin receptor 1A (5-HT1A) partial agonist for the treatment of major depressive disorder (MDD). The Company's second late-stage drug candidate is apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator in Phase III of clinical development for use in nuclear Single Photo Emission Computed Topography (SPECT) myocardial perfusion imaging. The Company also provides the FAMILION family of genetic tests for inherited cardiac syndromes, including cardiac channelopathies and cardiomyopathies. On September 30, 2009, the Company purchased all the assets of Epix Pharmaceuticals, Inc. (Epix).
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
North Wales, Pennsylvania, United States, North America
Founded on
January 1, 1969
Closed on
February 22, 2011
Exited on
May 16, 2006
Went public on
May 16, 2006
Delisted on
April 13, 2011
Stock symbol
CLDA
Non-profit?
No
Acquired?
No
Employees count
251-500